189 related articles for article (PubMed ID: 24386138)
1. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.
Santini D; Procopio G; Porta C; Ibrahim T; Barni S; Mazzara C; Fontana A; Berruti A; Berardi R; Vincenzi B; Ortega C; Ottaviani D; Carteni G; Lanzetta G; Virzì V; Santoni M; Silvestris N; Satolli MA; Collovà E; Russo A; Badalamenti G; Fedeli SL; Tanca FM; Adamo V; Maiello E; Sabbatini R; Felici A; Cinieri S; Tonini G; Bracarda S
PLoS One; 2013; 8(12):e83026. PubMed ID: 24386138
[TBL] [Abstract][Full Text] [Related]
2. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.
Silvestris N; Pantano F; Ibrahim T; Gamucci T; De Vita F; Di Palma T; Pedrazzoli P; Barni S; Bernardo A; Febbraro A; Satolli MA; Bertocchi P; Catalano V; Giommoni E; Comandone A; Maiello E; Riccardi F; Ferrara R; Trogu A; Berardi R; Leo S; Bertolini A; Angelini F; Cinieri S; Russo A; Pisconti S; Brunetti AE; Azzariti A; Santini D
PLoS One; 2013; 8(10):e74402. PubMed ID: 24204569
[TBL] [Abstract][Full Text] [Related]
3. Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.
Santini D; Pantano F; Riccardi F; Di Costanzo GG; Addeo R; Guida FM; Ceruso MS; Barni S; Bertocchi P; Marinelli S; Marchetti P; Russo A; Scartozzi M; Faloppi L; Santoni M; Cascinu S; Maiello E; Silvestris F; Tucci M; Ibrahim T; Masi G; Gnoni A; Comandone A; Fazio N; Conti A; Imarisio I; Pisconti S; Giommoni E; Cinieri S; Catalano V; Palmieri VO; Infante G; Aieta M; Trogu A; Gadaleta CD; Brunetti AE; Lorusso V; Silvestris N
PLoS One; 2014; 9(8):e105268. PubMed ID: 25170882
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
5. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
6. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
[TBL] [Abstract][Full Text] [Related]
8. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
10. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.
Santini D; Tampellini M; Vincenzi B; Ibrahim T; Ortega C; Virzi V; Silvestris N; Berardi R; Masini C; Calipari N; Ottaviani D; Catalano V; Badalamenti G; Giannicola R; Fabbri F; Venditti O; Fratto ME; Mazzara C; Latiano TP; Bertolini F; Petrelli F; Ottone A; Caroti C; Salvatore L; Falcone A; Giordani P; Addeo R; Aglietta M; Cascinu S; Barni S; Maiello E; Tonini G
Ann Oncol; 2012 Aug; 23(8):2072-2077. PubMed ID: 22219016
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
Saad F; Eastham JA
Semin Oncol; 2010 Jun; 37 Suppl 1():S38-44. PubMed ID: 20682371
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.
Takeda N; Isu K; Hiraga H; Shinohara N; Minami A; Kamata H
J Orthop Sci; 2012 Nov; 17(6):770-4. PubMed ID: 23053582
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features and Risk Factors of Skeletal-Related Events in Genitourinary Cancer Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
Owari T; Miyake M; Nakai Y; Morizawa Y; Itami Y; Hori S; Anai S; Tanaka N; Fujimoto K
Oncology; 2018; 95(3):170-178. PubMed ID: 29874673
[TBL] [Abstract][Full Text] [Related]
14. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.
Yasuda Y; Fujii Y; Yuasa T; Kitsukawa S; Urakami S; Yamamoto S; Yonese J; Takahashi S; Fukui I
Int J Clin Oncol; 2013 Oct; 18(5):877-83. PubMed ID: 22965827
[TBL] [Abstract][Full Text] [Related]
15. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
[TBL] [Abstract][Full Text] [Related]
16. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Langer C; Hirsh V
Lung Cancer; 2010 Jan; 67(1):4-11. PubMed ID: 19939491
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
18. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
Trinkaus M; Simmons C; Myers J; Dranatisaris G; Clemons M
Support Care Cancer; 2010 Feb; 18(2):197-203. PubMed ID: 19424729
[TBL] [Abstract][Full Text] [Related]
19. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
20. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
Saad F; Chen YM; Gleason DM; Chin J
Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
